AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ANIP

CAREY STEPHEN P. sold $207K of ANIP

CAREY STEPHEN P. (SVP & CFO) sold 2,850 shares of ANI PHARMACEUTICALS INC (ANIP) at $72.80 ($0.21M total) on 2026-08-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAREY STEPHEN P.
Published Sep 1, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 10:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIP
Bearish
medium confidence
Mentioned
$ANIP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPBearishLow
01

Why it matters

The CFO's sale reduces his ownership and may be interpreted as a negative signal, though the amount is modest.

02

Market read

Primary insider sale filing; modest impact but worth noting for short‑term traders.

03

What to watch

Potential tax planning or portfolio rebalancing could be driving the transaction rather than company outlook.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑08‑31

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ANIPBearishMedium confidence
Context

CFO Stephen Carey sold 2,850 shares for $207,480 via a 10b5‑1 plan, reducing his stake to 171,843 shares.

Expected impact

Modest downward pressure; price may dip 1‑2% in the next trading session.

Evidence & confidence

The sale amount is modest ($207k) but involves the CFO, suggesting a possible negative signal to the market.

Market effects

Sector

Minimal; the sale does not affect the broader pharmaceutical sector.

Regional

Limited to U.S. investors tracking ANI Pharmaceuticals.

Global

Low; no global macro implications.

Counterpoint

What could challenge this read

The sale may be routine under a pre‑arranged 10b5‑1 plan and not indicative of insider sentiment.

Key entities

  • Company
    ANI Pharmaceuticals Inc

    U.S. pharmaceutical company (ticker ANIP).

  • Executive
    Stephen P. Carey

    Senior Vice President & Chief Financial Officer of ANI Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIP insider trading history →

Related articles

$ANIPHighAI 9/10

ANI Pharmaceuticals Inc (ANIP) Q3 2026 Earnings Call Highlights: Strong Revenue Growth

ANI Pharmaceuticals (ANIP) reported Q3 2026 revenue of $290.8M (+28% YoY) and raised 2026 guidance. CEO Lalwani discussed a $560M cash offer for Aegidus Therapeutics, funded by cash and debt. Emcitate's U.S. pricing set at $74,026 per pack. Cortrophin demand exceeded expectations, causing temporary pharmacy bottlenecks. The company aims to expand prescriber base and identify more MCT8 deficiency patients.

finance.yahoo.com
$ANIPHighAI 8/10

ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript

ANI Pharma (ANIP) reported Q3 2026 revenue of $290.8M, up 28% YoY, with adjusted EBITDA of $82.3M, up 40% YoY. Rare disease revenues grew 36% YoY, while generics grew 11%. The company revised Cortrophin Gel revenue guidance to $480M-$500M for 2026, down from $520M-$540M, citing supply chain issues. ANIP also announced an offer to acquire Aegidus Therapeutics, aiming to expand its rare disease portfolio.

finance.yahoo.com
$ANIPHighAI 8/10

ANI Pharmaceuticals Q3 Earnings Call Highlights

ANI Pharmaceuticals reported Q3 revenue of $104.5M, up 11% YoY. The company announced a $434M acquisition of Egetis, adding rare disease drug EMCITATE, expected to close in late 2026. ANI raised its 2026 revenue forecast to $1.085B-$1.125B and expects EMCITATE to generate over $300M in peak sales. The company has $420.8M in cash and $616.9M in debt.

finance.yahoo.com
$ANIPHigh

ANI Pharmaceuticals (NASDAQ:ANIP) reports strong Q3 2026

ANI Pharmaceuticals reported Q3 2026 revenue of $290.8M, beating estimates by 4.3% and growing 27.6% YoY. Adjusted EPS of $2.70 beat estimates by 23.8%. The company reconfirmed its revenue guidance of $1.11B and raised its adjusted EPS guidance to $9.54. EBITDA guidance was set at $295M, above consensus. Operating margin increased to 18% from 15.9% YoY.

finance.yahoo.com